Seeking Alpha

Zami Aberman

 
ABOUT
Mr. Aberman joined Pluristem as Chairman & CEO in September 2005. Upon arrival he immediately changed the Company’s strategy towards cellular therapeutics. Mr. Aberman's vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy, combined with Pluristem’s 3D culturing technology, led to the development of a series of unique products.

Mr. Aberman has 20 years of experience in marketing and management within the high technology industry. He has held positions as Chief Executive Officer and Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, ...More
SNAPSHOT
  • Description: Company executive.
  • Interests: Tech stocks
COMPANY
Pluristem Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX ...More
BLOG
Currently, you have no blog details. Click edit to add blog details.
Book
Currently, you have no book details. Click edit to add book details.